Toll Free: 1-888-928-9744
Published: Dec, 2016 | Pages:
30 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
BioLingus AG - Product Pipeline Review - 2016 Summary Global Markets Direct's, 'BioLingus AG - Product Pipeline Review - 2016', provides an overview of the BioLingus AG's pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by BioLingus AG, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the pipeline therapeutic landscape of BioLingus AG - The report provides overview of BioLingus AG including its business description, key facts, and locations and subsidiaries - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report assesses BioLingus AG's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report features BioLingus AG's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects Reasons To Buy - Evaluate BioLingus AG's strategic position with total access to detailed information on its product pipeline - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for BioLingus AG - Identify potential new clients or partners in the target demographic - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding BioLingus AG's pipeline depth and focus of pipeline therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 BioLingus AG Snapshot 6 BioLingus AG Overview 6 Key Facts 6 BioLingus AG - Research and Development Overview 7 Key Therapeutic Areas 7 BioLingus AG - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 BioLingus AG - Pipeline Products Glance 11 BioLingus AG - Early Stage Pipeline Products 11 Preclinical Products/Combination Treatment Modalities 11 Discovery Products/Combination Treatment Modalities 12 BioLingus AG - Unknown Stage Pipeline Products 13 Unknown Products/Combination Treatment Modalities 13 BioLingus AG - Drug Profiles 14 aldesleukin - Drug Profile 14 Product Description 14 Mechanism Of Action 14 R&D Progress 14 Cellular Immunotherapy to Target Survivin for Oncology - Drug Profile 15 Product Description 15 Mechanism Of Action 15 R&D Progress 15 exenatide biobetter - Drug Profile 16 Product Description 16 Mechanism Of Action 16 R&D Progress 16 interferon alfa biobetter - Drug Profile 17 Product Description 17 Mechanism Of Action 17 R&D Progress 17 interferon gamma - Drug Profile 18 Product Description 18 Mechanism Of Action 18 R&D Progress 18 interleukin 2 - Drug Profile 19 Product Description 19 Mechanism Of Action 19 R&D Progress 19 Monoclonal Antibody to Inhibit IL-23 for Crohn's Disease and Psoriasis - Drug Profile 20 Product Description 20 Mechanism Of Action 20 R&D Progress 20 Synthetic Peptide to Agonize GLP-1 for Type 2 Diabetes - Drug Profile 21 Product Description 21 Mechanism Of Action 21 R&D Progress 21 Synthetic Peptide to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile 22 Product Description 22 Mechanism Of Action 22 R&D Progress 22 Synthetic Peptide to Inhibit TNF-Alpha for Rheumatoid Arthritis - Drug Profile 23 Product Description 23 Mechanism Of Action 23 R&D Progress 23 BioLingus AG - Pipeline Analysis 24 BioLingus AG - Pipeline Products by Target 24 BioLingus AG - Pipeline Products by Route of Administration 25 BioLingus AG - Pipeline Products by Molecule Type 26 BioLingus AG - Pipeline Products by Mechanism of Action 27 BioLingus AG - Locations And Subsidiaries 28 Head Office 28 Appendix 29 Methodology 29 Coverage 29 Secondary Research 29 Primary Research 29 Expert Panel Validation 29 Contact Us 29 Disclaimer 30
List of Tables BioLingus AG, Key Facts 6 BioLingus AG - Pipeline by Indication, 2016 8 BioLingus AG - Pipeline by Stage of Development, 2016 9 BioLingus AG - Monotherapy Products in Pipeline, 2016 10 BioLingus AG - Preclinical, 2016 11 BioLingus AG - Discovery, 2016 12 BioLingus AG - Unknown, 2016 13 BioLingus AG - Pipeline by Target, 2016 24 BioLingus AG - Pipeline by Route of Administration, 2016 25 BioLingus AG - Pipeline by Molecule Type, 2016 26 BioLingus AG - Pipeline Products by Mechanism of Action, 2016 27
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.